Back to discover
Disease

Depressive Disorder

Late-stage therapeutic developmentActively researchedSteady momentum
25
Publications
24
Clinical trials
8
Related conditions
1
Related treatments
2025
Latest publication
Current focus
Therapeutic developmentInflammation & immunityMetabolic & lifestyle factors

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical Milestones15View all 15
+7 more in the activity timeline below
Activity timeline15

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies

Approval — Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resi… (2019)

Duloxetineapproved

Approval — Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder. Duloxetine Ze… (2015)

Research-associated treatments

Clinical trials

16 sponsors · 7 new · 6 completed in the last 12 months (net +6)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2019emaApprovalEsketamine hydrochloride· Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. source ↗
2015emaApprovalDuloxetine· Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder. Duloxetine Zentiva is indicated in adults. source ↗
2015emaApprovalDuloxetine· Treatment of major depressive disorder Treatment of diabetic peripheral neuropathic pain Treatment of generalised anxiety disorder Duloxetine Viatris is indicated in adults source ↗
2014emaApprovalDuloxetine· Duloxetine Lilly is indicated in adults for: Treatment of major depressive disorder Treatment of diabetic peripheral neuropathic pain Treatment of generalised anxiety disorder Duloxetine Lilly is indicated in adults. source ↗
2004emaApprovalDuloxetine· Treatment of major depressive disorder. Treatment of diabetic peripheral neuropathic pain. Treatment of generalised anxiety disorder. Cymbalta is indicated in adults. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

25 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20032025
Most influential

Depression and pain comorbidity: a literature review.

Archives of internal medicine · 2003 · 2,335 cites

The Work and Social Adjustment Scale: a simple measure of impairment in functioning.

The British journal of psychiatry : the journal of mental science · 2002 · 1,672 cites

Depression in late life: review and commentary.

The journals of gerontology. Series A, Biological sciences and medical sciences · 2003 · 1,333 cites
Recent publications
Major themes8
  • Depressive Disorder8
  • Depression3
  • Hallucinogens3
  • Gastrointestinal Microbiome2
  • Stress, Psychological2
  • Suicidal Ideation2
  • Suicide2
  • Adaptation, Psychological1
Leading journals6
  • PLoS medicine2
  • The British journal of psychiatry : the journal of mental science2
  • Translational psychiatry2
  • Annual review of psychology1
  • Archives of general psychiatry1
  • Archives of internal medicine1
Leading researchers8
  • Agostini MA1
  • Akan M1
  • Alexopoulos AV1
  • Allen NB1
  • Anderson RJ1
  • Anderson WS1
  • Appelbaum LG1
  • Aubry M1
Affiliations (unnormalised)6
  • University College London2
  • Avicenne Hospital1
  • Aziz Sancar Institute of Experimental Medicine1
  • Basic Medical College1
  • Bezmialem Vakif University1
  • Cambridgeshire and Peterborough NHS Foundation Trust1

Related conditions

8 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Depressive disorder is an affective disorder marked by a persistently dysphoric mood or a sustained loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. The literature also treats it as a common condition with important implications for diagnosis, complications, and treatment.

Causes

The grounding supports a multifactorial etiology rather than a single cause. Review evidence points to biopsychosocial contributors in late-life depression, and to adverse experiences in childhood, depression and anxiety disorders in childhood and adolescence, sociocultural roles with related adverse experiences, and psychological attributes related to vulnerability to life events and coping skills. The literature also notes longitudinal links with overweight and obesity, but this is presented as an association rather than a proven cause.

Pathophysiology

The supplied literature indicates shared biological pathways and neurotransmitters between depression and pain, suggesting overlapping mechanisms in comorbid states. It also includes immunology and microbiology as covered aspects, and specifically co-studies the gastrointestinal microbiome, but the grounding does not provide a more detailed mechanism. Depression is also discussed in relation to stress, psychological adaptation, anxiety, and suicidal ideation, indicating involvement of stress-related and psychological processes.

Risk factors

Female sex is associated with higher prevalence, incidence, and morbidity risk beginning at mid-puberty and continuing through adult life. Adverse experiences in childhood, depression and anxiety disorders in childhood and adolescence, sociocultural roles with related adverse experiences, and psychological vulnerability to life events and coping difficulties are identified as likely contributors. Overweight and obesity are also longitudinally associated with depression in the reviewed literature.

Current standard of care

The grounding supports treatment at the level of therapy, drug therapy, and prevention and control, but does not provide specific regimens. It also indicates that antidepressant medications are used, with evidence reviewed for their benefits, and that therapy evidence has expanded in late-life depression. Psilocybin is co-studied, but the supplied material does not establish it as standard care.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.